NDAINTRAVENOUSSOLUTION
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
GANZYK-RTU (ganciclovir) by Bausch + Lomb is 12. First approved in 2017.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANZYK-RTU is a ready-to-use intravenous formulation of ganciclovir, an antiviral nucleoside analog with potent activity against cytomegalovirus (CMV). It is indicated for immunocompromised patients at risk of or diagnosed with CMV infection, particularly those with HIV/AIDS or post-transplant complications. The drug works by inhibiting viral DNA polymerase, preventing CMV replication in infected cells.
Peak8.1 years to LOE
Product is in peak commercial stage with stable market position; team size and growth trajectory unknown due to limited competitive and spending data.
Mechanism of Action
12.1 Mechanism of Action Ganciclovir is an antiviral drug with activity against CMV [see ]. 12.3 Pharmacokinetics Absorption At the end of a one hour intravenous infusion of 5 mg/kg ganciclovir, total AUC ranged between 22.1 ± 3.2 (n = 16) and 26.8 ± 6.1 mcg·hr/mL (n = 16) and C max ranged between…
Worked on GANZYK-RTU at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.